|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-9-12
|
|
pubmed:abstractText |
Using a mouse model of ependymoma-a chemoresistant brain tumor-we combined multicell high-throughput screening (HTS), kinome-wide binding assays, and in vivo efficacy studies, to identify potential treatments with predicted toxicity against neural stem cells (NSC). We identified kinases within the insulin signaling pathway and centrosome cycle as regulators of ependymoma cell proliferation, and their corresponding inhibitors as potential therapies. FDA approved drugs not currently used to treat ependymoma were also identified that posses selective toxicity against ependymoma cells relative to normal NSCs both in vitro and in vivo, e.g., 5-fluorouracil. Our comprehensive approach advances understanding of the biology and treatment of ependymoma including the discovery of several treatment leads for immediate clinical translation.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1878-3686
|
|
pubmed:author |
pubmed-author:ArnoldLeggy ALA,
pubmed-author:AtkinsonJennifer MJM,
pubmed-author:BoulosNidalN,
pubmed-author:CarcabosoAngel MonteroAM,
pubmed-author:EdenChrisC,
pubmed-author:EllisonDavid WDW,
pubmed-author:FéauClementineC,
pubmed-author:GajjarAmarA,
pubmed-author:GibsonPaulP,
pubmed-author:GilbertsonRichard JRJ,
pubmed-author:GuyR KiplinRK,
pubmed-author:JohnsonRobert ARA,
pubmed-author:KoulDimpyD,
pubmed-author:KranenburgTanya ATA,
pubmed-author:LibreE AEA,
pubmed-author:MohankumarKumarasamypet MKM,
pubmed-author:PhoenixTimothyT,
pubmed-author:PoppletonHelenH,
pubmed-author:PriebeWaldemarW,
pubmed-author:ShelatAnang AAA,
pubmed-author:StewartClinton FCF,
pubmed-author:TongYiaiY,
pubmed-author:WrightKarenK,
pubmed-author:YungW K AlfredWK
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
13
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
384-99
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21907928-Animals,
pubmed-meshheading:21907928-Boronic Acids,
pubmed-meshheading:21907928-Brain,
pubmed-meshheading:21907928-Brain Neoplasms,
pubmed-meshheading:21907928-Cell Proliferation,
pubmed-meshheading:21907928-Centrosome,
pubmed-meshheading:21907928-Drug Screening Assays, Antitumor,
pubmed-meshheading:21907928-Ependymoma,
pubmed-meshheading:21907928-Fluorouracil,
pubmed-meshheading:21907928-High-Throughput Screening Assays,
pubmed-meshheading:21907928-Insulin,
pubmed-meshheading:21907928-Mice,
pubmed-meshheading:21907928-Mice, Nude,
pubmed-meshheading:21907928-Neural Stem Cells,
pubmed-meshheading:21907928-Pyrazines,
pubmed-meshheading:21907928-Signal Transduction,
pubmed-meshheading:21907928-Tumor Cells, Cultured
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
|
|
pubmed:affiliation |
Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
